TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16922749
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (500 mug) prior to anaesthesia and postoperative intravenous patient-controlled analgesia with morphine
Study: 16922749
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous patient-controlled analgesia only
Study: 17848760
Drug: Esmolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (50 microg/kg loading dose followed by 100 microg/kg/hr infusion)
Study: 17848760
Drug: Diltiazem (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.15 mg/kg loading dose followed by 5 mg/hr infusion)
Study: 22108775
Drug: Rabeprazole 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 40 mg once daily
Study: 8268118
Drug: Saline (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (control for intravenous fentanyl)
Study: 3899165
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin pretreatment
Study: 29359480
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1000 mg omega-3 fatty acids)
Study: 27590865
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (8 weeks of daily sessions)
Study: 24846347
Drug: Brodalumab (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab (doses between 140 and 210 mg)
Study: 18076705
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg subcutaneously once weekly for 12 weeks
Study: 11529652
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg qid
Study: 7955975
Drug: Acute hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hypoglycaemia in insulin-dependent diabetic patients
Study: 7955975
Drug: Reference test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference test with normal plasma glucose levels in insulin-dependent diabetic patients
Study: 3616277
Drug: Type of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type of treatment within the family
Study: 21733605
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine supplementation (30g/day, 0.41g/kg/day)
Study: 8412294
Drug: Response Rate
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response Rate to Radiation Therapy in young cohort
Study: 8412294
Drug: Salvage Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage Therapy Response Rate
Study: 21311355
Drug: l-Arg HCl
Normalized name: L-Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: l-Arg HCl (30 g at 0.5 g·min(‐1))
Study: 18294115
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anticholinergic therapy with alpha1‐antagonists
Study: 10632419
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) for the first two cycles and human menopausal gonadotropin (hMG) for the last two cycles (CCHH)
Study: 10632419
Drug: Human menopausal
Normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human menopausal gonadotropin (hMG) for the first two cycles and clomiphene citrate (CC) for the last two cycles (HHCC)
Study: 27112041
Drug: Early fortification
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early fortification (EF) starting at 20 mL/kg/d
Study: 27112041
Drug: Delayed fortification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed fortification starting at 100 mL/kg/d
Study: 22507335
Drug: Loratadine syrup
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine syrup
Study: 22507335
Drug: Cyproheptadine HCl
Normalized name: cyproheptadine HCl
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine HCl solution
Study: 20215456
Drug: Standard glycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glycemia treatment
Study: 9273182
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) including three cycles of 5-fluorouracil (600 mg/m2/d), cisplatin (15 mg/m2/d), etoposide (50 mg/m2/d), hydroxyurea (1,500 mg/d)
Study: 9273182
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy and chest radiotherapy (CCRT) with cisplatin (20 mg/m2) and 5-fluorouracil (500 mg/m2) during radiotherapy
Study: 8077090
Drug: Lysine clonixinate
Normalized name: lysine clonixinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine clonixinate (125 mg, 1 or 2 tablets every 8 h for 48 h)
Study: 8077090
Drug: Paracetamol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (500 mg, 1 or 2 tablets every 8 h for 48 h)
Study: 31256650
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous (IV) TXA given prior to the skin incision
Study: 31256650
Drug: Double-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose regimen of 1 g IV TXA given prior to skin incision and at time of wound closure
Study: 31256650
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 g IV TXA given prior to skin incision and 1 g of intraoperative topical TXA
Study: 31256650
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 1950 mg oral TXA given two hours preoperatively, six hours postoperatively, and on the morning of postoperative day one
Study: 28944355
Drug: Immediate placement
Normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate placement of 6.0 to 8.0 mm wide diameter implants (immediate group; 50 patients)
Study: 28944355
Drug: Delayed placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed placement of 4.0 or 5.0 mm diameter implants (delayed group; 50 patients)
Study: 17404896
Drug: Oral bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bovine collagen
Study: 12101535
Drug: Intravenous pyelography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pyelography
Study: 9987703
Drug: Erythromycin 333
Normalized name: erythromycin 333 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 333 mg
Study: 9987703
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg
Study: 2272187
Drug: Sustained-release diclofenac
Normalized name: diclofenac Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release diclofenac sodium (100 mg)
Study: 27492799
Drug: Control implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implants (Osseotite) with dual acid‐etched (DAE) surface in the apical portion and a machined coronal part.
Study: 27492799
Drug: Test implants
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implants (Full Osseotite, FOSS) which were completely DAE.
Study: 27492799
Drug: Both control
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both control and test implants.
Study: 26647864
Drug: ESM self-monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESM self-monitoring with weekly feedback sessions
Study: 2751973
Drug: PGF2 alpha‐isopropylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2 alpha‐isopropylester eye drops (1.0 microgram daily or 0.5 microgram twice daily)
Study: 27277189
Drug: Sonidegib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib (200 mg single dose)
Study: 27277189
Drug: Sonidegib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib with esomeprazole (40 mg pre-treatment for 5 days, combination on day 6)
Study: 18711187
Drug: Reinduction chemotherapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction chemotherapy (three 35-day blocks) for early relapse (ER)
Study: 18711187
Drug: Reinduction chemotherapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction chemotherapy (three 35-day blocks) for late relapse (LR)
Study: 18711187
Drug: Reinduction chemotherapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction chemotherapy (three 35-day blocks) for MRD-negative patients
Study: 18711187
Drug: Reinduction chemotherapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction chemotherapy (three 35-day blocks) for MRD-positive patients
Study: 18711187
Drug: Reinduction chemotherapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction chemotherapy (three 35-day blocks)
Study: 10472596
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) 500 mg/24 h for 3 days
Study: 10472596
Drug: Cefuroxime (ACF)
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime (ACF) 500 mg/12 h for 10 days
Study: 6138592
Drug: Azathioprine and
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine and steroids (Control)
Study: 30667279
Drug: rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rivaroxaban 2.5 mg twice daily plus aspirin
Study: 24392086
Drug: Preventive medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive medication for osteoporosis (specific medication not detailed)
Study: 21725374
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with auto-SCT (Arm B)
Study: 21725374
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (Arm A)
Study: 19652123
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus sertraline (target doses of 15 to 20 mg of olanzapine per day plus masked sertraline at 150 to 200 mg per day)
Study: 19652123
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus placebo (target doses of 15 to 20 mg of olanzapine per day plus masked placebo)
Study: 19652123
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus sertraline and Olanzapine plus placebo
Study: 8971314
Drug: Paracetamol elixir
Normalized name: Soul Pattinson Childrens Paracetamol Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol elixir 40 mg/kg preoperatively (Group A)
Study: 8971314
Drug: Paracetamol suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol suppositories 40 mg/kg after induction of anaesthesia (Group B)
Study: 8971314
Drug: Paracetamol elixir
Normalized name: Soul Pattinson Childrens Paracetamol Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol elixir (Group A)
Study: 8971314
Drug: Paracetamol suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol suppositories (Group B)
Study: 8971314
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with plasma paracetamol concentrations above 0.07 mmol/l
Study: 30958329
Drug: Neck stabilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck stabilization exercise and breathing retraining exercise (15 minutes each) in addition to rehabilitation exercise treatment.
Study: 30958329
Drug: Breathing retraining
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing retraining exercise (30 minutes) in addition to rehabilitation exercise treatment.
Study: 19766902
Drug: Folate supplementation
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate supplementation (5mg daily for 8 weeks)
Study: 18044061
Drug: Anticholinergic bronchodilator
Normalized name: BRONCHODILATORS,ANTICHOLINERGIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic bronchodilator
Study: 18044061
Drug: β-agonist bronchodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-agonist bronchodilator
Study: 18044061
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of β-agonists and anticholinergics
Study: 18044061
Drug: β-agonists added
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-agonists added to anticholinergic or inhaled corticosteroid use
Study: 15110023
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 100 mg
Study: 7950288
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (6 x 50 mg Fe2+ aspartate/day)
Study: 7950288
Drug: Parenteral iron
Normalized name: Iron, parenteral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral iron therapy (0.75 mg/kg BW complex‐bound Fe3+ once a week by infusion)
Study: 2891224
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg once at night
Study: 31420120
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin for 21 consecutive days
Study: 25205008
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia plus treatment as usual (TAU)
Study: 16505644
Drug: L-alanyl-L-glutamine dipeptide
Normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanyl-L-glutamine dipeptide (0.5 g.kg‐1.day‐1; Ala‐Gln group, n=58)
Study: 16505644
Drug: L-alanine+L-proline (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanine+L-proline (control group, n=56)
Study: 14768792
Drug: Mega-dose methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mega-dose methylprednisolone (MDMP) 30 mg/kg/d for 3 days and 20 mg/kg/d for 4 days
Study: 14768792
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg/d for 2 days
Study: 4038511
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous metoclopramide (MCP) at a dose of 2 mg/kg IV for three doses
Study: 4038511
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-dose intravenous metoclopramide (MCP) and intravenous dexamethasone (DXM) at a dose of 20 mg IV for three doses
Study: 23973522
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg once daily for 4 weeks, with possible increase to 8 mg based on investigator discussion.
Study: 23973522
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg once daily (with option to decrease to 4 mg).
Study: 18588561
Drug: salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol/fluticasone propionate combination
Study: 15966221
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy group (n=7) with novel arterial infusion regimen using cisplatin (CDDP) and 5‐fluorouracil (5‐FU)
Study: 15966221
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=8) with no adjuvant chemotherapy
Study: 15966221
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy group (n=7)
Study: 7773582
Drug: High-dose oral/intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral/intravenous fluconazole (400 mg daily)
Study: 7773582
Drug: Oral nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nystatin plus miconazole inhalations
Study: 2275309
Drug: Topical zinc
Normalized name: bacitracin topical zinc compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical zinc oxide
Study: 7404497
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) heparin
Study: 7404497
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) heparin
Study: 24298982
Drug: Cylindrical implant
Normalized name: Imperata cylindrica root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylindrical implant
Study: 24298982
Drug: Conical/cylindrical implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical/cylindrical implant
Study: 19345510
Drug: Acamprosate (1998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (1998 mg daily) during Detoxification Phase (5-14 days)
Study: 19345510
Drug: Acamprosate (1998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (1998 mg daily) during Rehabilitation Phase (after detoxification)
Study: 11170991
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of RTS,S/SBAS2
Study: 11170991
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of RTS,S/SBAS2
Study: 11170991
Drug: 3 standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 standard doses of RTS,S/SBAS2
Study: 11170991
Drug: 3 one-half
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 one-half doses of RTS,S/SBAS2
Study: 11170991
Drug: 3 one-fifth
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 one-fifth doses of RTS,S/SBAS2
Study: 9779247
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and systemic medication
Study: 8154950
Drug: Antibiotic consultant
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic consultant
Study: 3337344
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (pH, 5.5) 3 mg/kg
Study: 3337344
Drug: Alkalinized bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinized bupivacaine 0.5% (pH, 7.05-7.15) 3 mg/kg
Study: 1347293
Drug: Intensive pharmacotherapy
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive pharmacotherapy
Study: 21725168
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment - 1 Hz.
Study: 19408036
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata (Paractin) tablets, 30% total andrographolides, administered three times a day for 14 weeks
Study: 19408036
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata (Paractin) tablets
Study: 17525777
Drug: Lumbar facet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar facet joint nerve blocks using bupivacaine and steroids (Group III)
Study: 17525777
Drug: Lumbar facet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar facet joint nerve blocks using bupivacaine, Sarapin, and steroids (Group IV)
Study: 17525777
Drug: Non-steroid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid group (Groups I and II)
Study: 17525777
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (Groups III and IV)
Study: 6242150
Drug: HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB vaccine (5 micrograms, 3 injections at one-month intervals plus a booster after one year)
Study: 6242150
Drug: HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB vaccine (5 micrograms, 2 doses given at intervals of 2 or 6 months plus a booster after one year)
Study: 6242150
Drug: HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB vaccine
Study: 6242150
Drug: HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB vaccine and DT-polio vaccine administered simultaneously
Study: 16479196
Drug: Native Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native Escherichia coli L‐asparaginase (Crasnitin; n = 10)
Study: 16479196
Drug: L‐asparaginase derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐asparaginase derived from Erwinia chrysanthemi (Erwinase; n = 10)
Study: 3954392
Drug: Treatment discontinuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment discontinuation due to adverse reactions
Study: 23163735
Drug: Conventional obesity
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional obesity therapy (COT)
Study: 8403798
Drug: Bombesin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bombesin infusion
Study: 3311923
Drug: Megestrol acetate/tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol acetate/tamoxifen (20 mg/day)
Study: 24284856
Drug: Transdermal VALE-ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal VALE-ibuprofen (200 mg ibuprofen, 2.0 grams of drug product applied twice daily for 14 days)